Researchers at Tufts University have come up with a resorbable electronic implant that when used in mice was able to be triggered remotely by wireless signal and deliver heat to infected tissue.
IDEXX Laboratories and Hill's Pet Nutrition teamed up with researchers at Oregon State University to develop a new biomarker, called SDMA. The scientist showed that the biomarker could spot kidney disease an average of 17 months earlier than currently used approaches--and in one case, a full four years earlier.
Bristol-Myers Squibb has signed a deal with Five Prime Therapeutics to determine whether a combination of its star immuno-oncology contender and the biotech's antibody can make a difference in a range of cancers.
Amgen is calling off all clinical studies on rilotumumab in advanced gastric cancer after a peek at Phase III data revealed that the drug was actually making matters worse for patients, further marring the value of the company's oncology pipeline.
Medidata and partner TransCelerate BioPharma, a nonprofit run by the world's largest drugmakers, are amplifying their call for clinical trial runners to embrace new technology, unveiling study results that support the adoption of risk-based monitoring.
Diagnostic smartphone apps are proliferating. No, these apps don't somehow turn the phone into a needle for drawing blood; instead they monitor stuff we take for granted, like talking or the movement of our eyes.
Proponents of DNA printing have heralded it as a way to do everything from bringing alien life back from Mars to delivering vaccines in the event of a pandemic. And the technology has attracted GlaxoSmithKline and Roche, both of which have taken an interest in Cambrian Genomics.
BioNano Genomics has restocked its coffers to fund an assault on the genome analysis sector. The San Diego, CA-based genome mapping firm raised a $53 million war chest from Novartis' venture fund and other investors to accelerate uptake of its Irys DNA analysis device and accompanying software.
Amid growing demand for portable, low-cost diagnostics, Indian startup Swasthya Slate is developing a device that could help reduce costs and improve outcomes for patients in developing countries.
Boston Scientific's Synergy bioabsorbable polymer drug-eluting stent is on track for FDA approval after the successful Evolve II clinical trial, experts said, citing data released yesterday at the American Heart Association meeting in Chicago.